Eli Lilly Signs $2.75 Billion AI Drug Discovery Deal with Insilico Medicine

Eli Lilly and Insilico Medicine have announced a global AI-driven drug discovery collaboration worth up to $2.75 billion.

The agreement grants Lilly an exclusive worldwide license for the development, manufacturing, and commercialization of novel oral therapeutics currently in preclinical development. Insilico receives a $115 million upfront payment, with the remainder structured as development, regulatory, and commercial milestones plus tiered royalties.

Insilicos Pharma.AI platform uses generative AI to accelerate the entire pipeline from target identification to drug design. The company has demonstrated that AI can dramatically reduce the time needed to bring a drug candidate from concept to clinical stage.

The deal builds on an existing AI software licensing agreement from 2023 and a research partnership from November 2025. It represents one of the largest AI-driven pharma deals ever, signaling that Big Pharma is now investing billions in AI as a core drug discovery technology.

For CIOs and technology leaders, this is a clear signal: AI-driven research has moved beyond the experimental phase. It has become a strategic imperative that pharmaceutical companies are willing to pay billions for.